Last week’s other top-gaining TSX stocks were Lydian International, Wellgreen Platinum, Trevali Mining and Alamos Gold.
The Board of Ormonde (LON:ORM) is pleased to provide an update of construction activities for the Barruecopardo Project in Salamanca, Spain (“Barruecopardo” or the “Project”).
Following a period of review of the construction schedule, the Board of the Project company, Saloro SLU (“Saloro”), has authorised the issuance of outstanding approvals on
Wallbridge Mining Company Ltd. (TSX:WM, FWB:WC7) is pleased to announce that the initial results from Wallbridge’s first drilling program on its 100% owned Fenelon Gold property (“Fenelon”) in Quebec have exceeded expectations and have confirmed the resource expansion potential on the property. The exploration drill program at Fenelon commenced
Falco Resources Ltd. (TSXV:FPC) has made the following appointments: Bryan A. Coates, president of Osisko Gold Royalties Ltd., will be joining the board of directors and will chair a newly formed finance committee of the board of directors. Hélène Cartier, who currently sits on the Board of Directors, will join
Wallbridge Mining Company Ltd. (TSX:WM, FWB:WC7) has commenced resource expansion drilling at its 100-per-cent-owned Fenelon gold mine property in Quebec.
Falco Resources Ltd. (TSX.V: FPC) is pleased to announce that it is initiating exploration activities on its large 668 square kilometre land package in the Rouyn-Noranda Camp, which surrounds it’s 100% owned Horne 5 Project. The planned 40,000 metre exploration drill campaign is part of a $10 million budget
Rockcliff Copper Corporation (“Rockcliff” or the “Company”) (TSXV:RCU)(FRANKFURT:RO0)(WKN:A142TR) is pleased to announce drill hole assay results from its on-going Phase 2 drill program on the Talbot Property, Manitoba. Additional geophysical resurveying of historical drill holes has discovered a conductive plate immediately below and down dip of the main lens of
Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the UHN’s Princess Margaret Cancer Centre (PM) will conduct a Phase 2 clinical trial to evaluate the use of a combination of immunotherapies from Immunovaccine and Merck (known as MSD outside the United States and Canada).
Clinical investigators will assess
Trevali Mining VP of Investor Relations, Steve Stakiw, provided his insight, forecast and advice for investors interested in the base metal. He shares with INN what to look for and what catalysts to watch out for.